FibroGen, Inc. (FGEN)
NASDAQ: FGEN · Real-Time Price · USD
5.75
+0.59 (11.43%)
At close: Jun 20, 2025, 4:00 PM
5.87
+0.12 (2.09%)
After-hours: Jun 20, 2025, 4:08 PM EDT
FibroGen Revenue
FibroGen had revenue of $2.74M in the quarter ending March 31, 2025, a decrease of -89.20%. This brings the company's revenue in the last twelve months to $7.00M, down -80.57% year-over-year. In the year 2024, FibroGen had annual revenue of $29.62M, down -36.71%.
Revenue (ttm)
$7.00M
Revenue Growth
-80.57%
P/S Ratio
3.31
Revenue / Employee
$31,093
Employees
225
Market Cap
23.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 29.62M | -17.18M | -36.71% |
Dec 31, 2023 | 46.80M | -93.93M | -66.74% |
Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
FGEN News
- 7 days ago - Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
- 8 days ago - FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewsWire
- 11 days ago - FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - GlobeNewsWire
- 5 weeks ago - FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen) - GlobeNewsWire
- 6 weeks ago - FibroGen to Report First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire